Literature DB >> 6139756

Pharmacokinetics of phenobarbital and propylhexedrine after administration of barbexaclone in the mouse.

H Iven, E Feldbusch.   

Abstract

The antiepileptic barbexaclone is the salt of the base propylhexedrine (indirect sympathomimetic) and phenylethylbituric acid. After i.v. and oral administration of 66 mg/kg barbexaclone to mice the time course of propylhexedrine and phenobarbital concentrations was studied in plasma, brain, lung, liver, kidney, spleen, heart, and skeletal muscle. Furthermore, the kinetics of phenobarbital were studied after treatment with an equimolar dose of phenobarbital-Na (40 mg/kg). In contrast to the i.v. bolus of phenobarbital-Na, barbexaclone was non-lethal only when infused over a period of 3 min. After the i.v. administration of either salt, phenobarbital plasma levels declined monoexponentially with a half-life of 7.5 h; the volume of distribution was 0.78 l/kg. After oral application absorption of phenobarbital was complete with both salts, though it was delayed after barbexaclone. The latter was the result of a delayed gastro-intestinal passage. Brain uptake of phenobarbital was a slow process, equilibrium with plasma concentrations being reached only 30 min after injection. Propylhexedrine reduced phenobarbital concentrations in brain as evident from steady state tissue-plasma ratios. This was observed after i.v. as well as after oral application. After i.v. application of barbexaclone the following pharmacokinetic parameters for propylhexedrine were determined: t0.5 alpha 0.31 h, t0.5 beta 2.5 h, Vd beta 19.3 l/kg; bioavailability (AUC oral/AUC i.v.) 0.37. Propylhexedrine penetrated the blood-brain barrier rapidly. High but unequal tissue accumulation was observed: lung = kidney greater than liver = brain greater than spleen greater than heart greater than skeletal muscle.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6139756     DOI: 10.1007/bf00497022

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  26 in total

1.  [EFFECT AND INDICATION OF A NEW ANTIEPILEPTIC DRUG].

Authors:  H PENIN
Journal:  Dtsch Med Wochenschr       Date:  1964-09-04       Impact factor: 0.628

2.  [THE MECHANISM OF ACTION OF L-1-CYCLOHEXYL-2-METHYLAMINOPROPAN-5,5-PHENYLETHYLBARBITURATE AND ITS SUITABILITY AS AN ANTIEPILEPTIC. COMPARATIVE STUDIES WITH PHENOBARBITAL].

Authors:  H HAAS
Journal:  Arzneimittelforschung       Date:  1963-08

3.  The distribution and excretion of phenobarbital.

Authors:  W J WADDELL; T C BUTLER
Journal:  J Clin Invest       Date:  1957-08       Impact factor: 14.808

4.  Studies on sympathomimetic amines. II. The biotransformation and physiological disposition of d-amphetamine, d-p-hydroxyamphetamine and d-methamphetamine.

Authors:  J AXELROD
Journal:  J Pharmacol Exp Ther       Date:  1954-03       Impact factor: 4.030

5.  [Clinical trial with a new anti-epileptic: barbexaclone].

Authors:  J H Bragatti; G H Caleffi; F J Prenna
Journal:  Arq Neuropsiquiatr       Date:  1977-09       Impact factor: 1.420

Review 6.  The influence of environmental temperature on the concentration of pentobarbital and barbital in the liver and brain. An experimental study on guinea pigs.

Authors:  E Sotaniemi
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1967

7.  [Experience with Maliasin in the treatment of epileptic children (preliminary report)].

Authors:  I Schiefer; F J Breyer; D Scheffner
Journal:  Med Welt       Date:  1968-11-02

8.  Blood-brain barrier transfer and cerebral uptake of antiepileptic drugs.

Authors:  O B Paulson; A Györy; M M Hertz
Journal:  Clin Pharmacol Ther       Date:  1982-10       Impact factor: 6.875

9.  Intravenous prophylhexedrine (Benzedrex®) abuse and sudden death.

Authors:  R J Anderson; H R Garza; J C Garriott; V Dimaio
Journal:  Am J Med       Date:  1979-07       Impact factor: 4.965

10.  Relationships between plasma concentrations of diphenylhydantoin, phenobarbital, carbamazepine, and 3-sulfamoylmethyl-1,2-benzisoxazole (AD-810), a new anticonvulsant agent, and their anticonvulsant or neurotoxic effects in experimental animals.

Authors:  Y Masuda; Y Utsui; Y Shiraishi; T Karasawa; K Yoshida; M Shimizu
Journal:  Epilepsia       Date:  1979-12       Impact factor: 5.864

View more
  5 in total

1.  Constitutive androstane receptor -null mice are sensitive to the toxic effects of parathion: association with reduced cytochrome p450-mediated parathion metabolism [corrected].

Authors:  Linda C Mota; Juan P Hernandez; William S Baldwin
Journal:  Drug Metab Dispos       Date:  2010-06-23       Impact factor: 3.922

2.  A recursive-partitioning model for blood-brain barrier permeation.

Authors:  S R Mente; F Lombardo
Journal:  J Comput Aided Mol Des       Date:  2005-12-06       Impact factor: 3.686

3.  The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice.

Authors:  Geoffrey J Markowitz; Shilpa D Kadam; Dawn M Boothe; Natasha D Irving; Anne M Comi
Journal:  Neuroreport       Date:  2010-04-21       Impact factor: 1.837

4.  Comparative kinetics of phenobarbital after administration of the acid and the propylhexedrine salt (barbexaclone).

Authors:  E Perucca; R Grimaldi; G Ruberto; C Gelmi; F Trimarchi; A Crema
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

5.  Mechanistic modelling of enzyme-restoration effects of new recombinant liver-targeted proteins in acute intermittent porphyria.

Authors:  Diego Vera-Yunca; Karol M Córdoba; Zinnia P Parra-Guillen; Daniel Jericó; Antonio Fontanellas; Iñaki F Trocóniz
Journal:  Br J Pharmacol       Date:  2022-03-21       Impact factor: 9.473

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.